CD80 and neoplasm: CTLA-4 competes with the costimulatory receptor CD28 for binding B7 molecules (CD80/86) on antigen-presenting cells, while PD-1 inhibits TCR signaling upon engagement with PD-L1 on tumor or immune cells.